Aphena Names Shawn Reilley New CEO

Aphena Placeholder logo
Reilley Considered Ideal Candidate to Continue Company's Growth

EASTON, Maryland — Aphena Pharma Solutions recently announced that Kevin Kerchner is retiring from his role as CEO and that, effective Dec. 3, Shawn Reilley has replaced Kerchner as the new CEO of the pharmaceutical packaging and manufacturing company.

"Under Kevin's leadership, working with Aphena's management team and our employees, the company has made a dramatic turnaround and is well positioned for continued growth and success," said Matthew Thompson, a member of Aphena's board of directors. "Aphena now has a clear mission and vision, a strong financial foundation and significant opportunities for its future."

After an extensive search, Aphena's board identified Reilley as an ideal candidate to lead the company on a continued path of growth into the future. Reilley has a bachelor of science and an MBA in finance from Miami University in Oxford, Ohio, and brings a strong executive and sales background to Aphena. Most recently, he was president of Advanced Plastics Processing Technologies for Milacron LLC.

Prior to Milacron, Reilley was president of Anderson Brecon (formerly Anderson Packaging), an industry-leading solid-dose contract packaging company.

"Shawn's experience with Anderson Packaging and leading a regulated, pharmaceutical contract organization will serve our company well moving forward," said Thompson.

"I'm excited to join Aphena at this pivotal point in the company's history," said Reilley. "It is a privilege to be part of a company that is so committed to steady, planned investment in expansion to provide its customers with one of the broadest ranges of capabilities in the industry. I'm looking forward to leading Aphena through its next phase of innovation and exponential growth."

Aphena Pharma Solutions is an industry-leading organization providing turnkey contract packaging and manufacturing solutions for the pharmaceutical, OTC, dietary supplement, animal health, consumer health and medical device markets. With two separate FDA- and DEA-registered, GDUFA-compliant and serialization-ready sites in the U.S., Aphena handles solid dose, liquids, gels, creams, ointments, foams, suspensions and lotions.

For more information about Aphena Pharma, visit aphenapharma.com or call 1-866-465-4506.